Novo Nordisk A/S
CSE:NOVO B
Novo Nordisk A/S
CSE:NOVO B
Price:
871.8 DKK
-2.89%
Updated:
May 2, 2024
Novo Nordisk A/S
Cash from Financing Activities
|
Novo Nordisk A/S
Cash from Financing Activities Peer Comparison
Comparables:
HLUN A
ALK B
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Novo Nordisk A/S
CSE:NOVO B
|
Cash from Financing Activities
-kr63.2B
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-10%
|
|
|
H Lundbeck A/S
CSE:HLUN A
|
Cash from Financing Activities
-kr2.1B
|
CAGR 3-Years
5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ALK-Abello A/S
CSE:ALK B
|
Cash from Financing Activities
-kr31m
|
CAGR 3-Years
21%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
See Also
What is Novo Nordisk A/S's Cash from Financing Activities?
Cash from Financing Activities
-63.2B
DKK
-63.2B
DKK
Based on the financial report for Dec 31, 2023, Novo Nordisk A/S's Cash from Financing Activities amounts to -63.2B DKK.
What is Novo Nordisk A/S's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
-10%
-10%
Over the last year, the Cash from Financing Activities growth was -22%. The average annual Cash from Financing Activities growth rates for Novo Nordisk A/S have been -25% over the past three years , -13% over the past five years , and -10% over the past ten years .
You don't have any saved screeners yet
